SK Biopharmaceuticals Co Ltd represents values such as innovation, integrity, and collaboration. The company's corporate philosophy revolves around creating innovative solutions to improve the lives of patients worldwide. SK Biopharmaceuticals Co Ltd is committed to conducting business with the utmost integrity, ensuring transparency, and adhering to ethical standards. The company strives to foster a collaborative environment, working together with partners and stakeholders to drive advancements in the biopharmaceutical industry. With a focus on research and development, SK Biopharmaceuticals Co Ltd aims to bring groundbreaking treatments and therapies to patients, reflecting its dedication to improving global healthcare.

SK Biopharmaceuticals Co Ltd is primarily present in South Korea.

SK Biopharmaceuticals Co Ltd has achieved several significant milestones. Firstly, the company successfully developed and obtained approval for its innovative epilepsy treatment, cenobamate, in the United States. This achievement marks a major breakthrough in the treatment of epilepsy. Additionally, SK Biopharmaceuticals Co Ltd has entered into numerous global partnerships and collaborations, expanding its reach in the pharmaceutical industry. The company has also made substantial progress in its pipeline, advancing the development of various neurologic and psychiatric disorders treatments. With these achievements, SK Biopharmaceuticals Co Ltd has further solidified its position as a leading player in the biopharmaceutical sector.

SK Biopharmaceuticals Co Ltd is a leading biopharmaceutical company with a rich history and background. Established in 1993, the company specializes in research, development, and manufacturing of innovative therapeutics. Headquartered in South Korea, SK Biopharmaceuticals has expanded its global presence through strategic partnerships and collaborations. With a focus on neurological disorders and other therapeutic areas, the company has developed breakthrough drugs such as XYREM®, which is used to treat narcolepsy. SK Biopharmaceuticals Co Ltd has built a strong reputation for its cutting-edge research, commitment to scientific excellence, and dedication to improving patients' lives.

The main competitors of SK Biopharmaceuticals Co Ltd in the market include major players like Johnson & Johnson, Pfizer Inc., and Novartis AG. These companies, along with SK Biopharmaceuticals, are engaged in the research, development, and commercialization of innovative biopharmaceutical products. With its strong portfolio and market presence, SK Biopharmaceuticals competes fiercely and continuously strives to maintain its position among these industry giants.

SK Biopharmaceuticals Co Ltd is primarily active in the pharmaceutical industry.

The business model of SK Biopharmaceuticals Co Ltd revolves around the development and commercialization of innovative pharmaceutical products. As a global biopharmaceutical company, SK Biopharmaceuticals focuses on researching, discovering, and developing novel treatments for various diseases. This includes conducting rigorous clinical trials, obtaining regulatory approvals, and engaging in strategic partnerships for the commercialization of their products. With a strong emphasis on research and development, SK Biopharmaceuticals aims to bring forth cutting-edge therapies to improve patients' lives and address unmet medical needs.

مُعامل القيمة السوقية إلى الأرباح لـ SK Biopharmaceuticals Co هو ١٢٩٫٣٥.

مُعامِل القيمة إلى المبيعات SK Biopharmaceuticals Co هو ١٦٫٧٠.

نقاط جودة AlleAktien لـ SK Biopharmaceuticals Co هي 3/10.

المتوقعة SK Biopharmaceuticals Co الإيرادات هي ٥١٨٫٢٣ مليارات KRW.

صافي الربح المتوقعة SK Biopharmaceuticals Co هو ٦٦٫٩٠ مليارات KRW.

SK Biopharmaceuticals Co Ltd (SK biopharm) is a leading South Korean company specializing in the development and commercialization of innovative drugs for the treatment of central nervous system (CNS) disorders and other major diseases. The company is committed to promoting better health for patients worldwide through its research and development. SK biopharm has several business areas, including research and development (R&D), production, and distribution of pharmaceuticals. The R&D division is the core of the company, focusing on the discovery, development, and commercialization of new drugs and therapeutic approaches. SK biopharm invests significantly in R&D and has built a comprehensive research platform that combines expertise in medicine, chemistry, pharmacology, toxicology, and biology. SK biopharm offers a wide range of products available in various countries worldwide. One of the company's key products is the anticonvulsant XCOPRI® (Cenobamate), which is approved in the US, Europe, and China. XCOPRI® was developed to help patients with partial-onset seizures, one of the most common forms of epilepsy. XCOPRI® has proven to be highly effective and safe, showing promising results in clinical trials. Another important product from SK biopharm is the antidepressant Vilazodone (trade name Viibryd), approved for the treatment of depression in adults. Viibryd has shown good efficacy due to its unique dual action on serotonin receptors and serotonin transporters. SK biopharm also has a wide range of products in its R&D pipeline, including new therapies for the treatment of epilepsy, schizophrenia, and pain. SK biopharm pursues a global expansion strategy and has offices in North America, Europe, and Asia. The company has established strategic partnerships with some of the world's leading pharmaceutical companies to accelerate the development and commercialization of its products worldwide. SK biopharm has also formed partnerships with academic institutions and research institutes around the world to drive innovation in medicine. To foster growth, SK biopharm has established a strong corporate culture that promotes innovation, collaboration, and entrepreneurial virtues. The company has an experienced management team and a dedicated research team focused on developing drugs that have the potential to improve the lives of people worldwide. Overall, SK biopharm has an impressive track record in developing and commercializing innovative drugs for a variety of CNS disorders. With its R&D pipeline, wide product range, and strategic partnerships, SK biopharm is well-positioned to continue helping patients worldwide and promoting better health for all.

يوزع SK Biopharmaceuticals Co أرباحًا قدرها 0 KRW من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ SK Biopharmaceuticals Co في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـSK Biopharmaceuticals Co هو KR7326030004.

الرمز المُختصر لـ SK Biopharmaceuticals Co هو 326030.KS.

خلال آخر 12 شهراً، دفعت SK Biopharmaceuticals Co توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع SK Biopharmaceuticals Co خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 KRW.

نسبة توزيعات الأرباح الحالية لـ SK Biopharmaceuticals Co هي .

SK Biopharmaceuticals Co يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

SK Biopharmaceuticals Co دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 KRW. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

SK Biopharmaceuticals Co يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 KRW من SK Biopharmaceuticals Co المُعلن عنها في ٢٥‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٥‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٥‏/٩‏/٢٠٢٤.

في العام 2023، وزعت SK Biopharmaceuticals Co 0 KRW كأرباح أسهم.

يتم توزيع أرباح SK Biopharmaceuticals Co بالعملة KRW.